HPV Infection & Spontaneous Clearance
Nearly every sexually active adult acquires HPV at some point.
- ~80%: Lifetime HPV exposure (of sexually active adults)
- ~70%: Cleared within 1 year (by host immune response)
- ~90%: Cleared within 2 years (cumulative clearance rate)
- ~14: High-risk HPV types (linked to cervical cancer)
How HPV enters the epithelium
HPV infects basal cells through microabrasions in tissue.
The immune response
T-cells and local immunity clear most infections silently.
Roughly 9 in 10 HPV infections clear without ever causing dysplasia.
Why some infections persist
Viral immune-evasion proteins can suppress local clearance.
Persistent Infection Beyond Two Years
Persistence, not exposure, is the real driver of cancer risk.
- ~10%: Persist beyond 2 years (of initial infections)
- ~24: Median time to persistence (months post-infection)
- HPV-16: Dominant persistent type (highest oncogenic risk)
- 2×: Smoking risk multiplier (higher persistence odds)
Viral integration into the genome
HPV DNA can integrate into host chromosomes over time.
Oncoprotein expression
E6 and E7 proteins disable key tumor-suppressor pathways.
E6 degrades p53; E7 inactivates Rb — both drive unchecked cell division.
Cofactors that favor persistence
Smoking, immunosuppression, and coinfections raise risk.
CIN1–2 — Cervical Intraepithelial Neoplasia
Persistent HPV begins reshaping the cervical epithelium.
- ~60%: CIN1 spontaneous regression (resolve without treatment)
- ~40%: CIN2 spontaneous regression (within 2 years)
- ~11%: CIN1→CIN3 progression (over 2–4 years)
- Pap/HPV: Typical detection method (cytology screening)
CIN1 — mild dysplasia
Abnormal cells confined to the lower third of epithelium.
CIN2 — moderate dysplasia
Atypia extends into the lower two-thirds of tissue.
Many CIN1–2 lesions still regress on their own without treatment.
Why screening matters here
Routine cytology catches change before cancer develops.
CIN3 — Severe Dysplasia
CIN3 is the last reversible step before invasive disease.
- ~30%: CIN3 untreated → cancer (over 20–30 years)
- ~30%: CIN3 spontaneous regression (lower than CIN1–2)
- >90%: Treatment cure rate (with LEEP excision)
- 25–35: Median age at diagnosis (years)
Full-thickness atypia
Abnormal cells now span the entire epithelial layer.
The membrane still holds
Cells have not yet crossed the basement membrane.
CIN3 is highly treatable — this is the critical intervention window.
Why treatment is offered now
Excision at CIN3 prevents almost all future cancers.
Invasive Cervical Cancer
Without vaccination, screening, or treatment, cancer can follow.
- ~660K: Global cases per year (new diagnoses)
- 10–15: Typical latency from CIN3 (years untreated)
- >90%: 5-year survival, early stage (when caught early)
- ~90%: Deaths preventable by vaccine (of HPV-driven cases)
Basement membrane breach
Cells invade the stroma and gain access to vasculature.
Local and distant spread
Angiogenesis and lymphatic invasion enable metastasis.
This entire pathway is preventable — vaccination stops it at step one.
The prevention window
Vaccination plus screening can make this stage rare.